These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 20572430)
1. Utility of routine nurse assessment of the risk of chemotherapy-induced febrile neutropenia. Moore K; Fortner B Can Oncol Nurs J; 2010; 20(2):75-9. PubMed ID: 20572430 [TBL] [Abstract][Full Text] [Related]
2. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses. Kearney N; Friese C Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720 [TBL] [Abstract][Full Text] [Related]
3. Oncology nurses' use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia. Nirenberg A; Reame NK; Cato KD; Larson EL Oncol Nurs Forum; 2010 Nov; 37(6):765-73. PubMed ID: 21059588 [TBL] [Abstract][Full Text] [Related]
6. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939 [TBL] [Abstract][Full Text] [Related]
7. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C; Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116 [TBL] [Abstract][Full Text] [Related]
8. Colony-stimulating factors for the management of neutropenia in cancer patients. Dale DC Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591 [TBL] [Abstract][Full Text] [Related]
9. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C; Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358 [TBL] [Abstract][Full Text] [Related]
10. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Schelenz S; Giles D; Abdallah S Ann Oncol; 2012 Jul; 23(7):1889-93. PubMed ID: 22048152 [TBL] [Abstract][Full Text] [Related]
11. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. Donohue R Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450 [TBL] [Abstract][Full Text] [Related]
12. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy. Chia VM; Page JH; Rodriguez R; Yang SJ; Huynh J; Chao C Breast Cancer Res Treat; 2013 Apr; 138(2):621-31. PubMed ID: 23468242 [TBL] [Abstract][Full Text] [Related]
13. Evidence-based care for the neutropenic patient with leukemia. Shelton BK Semin Oncol Nurs; 2003 May; 19(2):133-41. PubMed ID: 12830737 [TBL] [Abstract][Full Text] [Related]
14. Using a computer-based risk assessment tool to identify risk for chemotherapy-induced febrile neutropenia. Miller K Clin J Oncol Nurs; 2010 Feb; 14(1):87-91. PubMed ID: 20118031 [TBL] [Abstract][Full Text] [Related]
15. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. Ammann RA; Bodmer N; Hirt A; Niggli FK; Nadal D; Simon A; Ozsahin H; Kontny U; Kühne T; Popovic MB; Lüthy AR; Aebi C J Clin Oncol; 2010 Apr; 28(12):2008-14. PubMed ID: 20231680 [TBL] [Abstract][Full Text] [Related]
16. A European survey relating to cancer therapy and neutropenic infections: nurse and patient viewpoints. Leonard K Eur J Oncol Nurs; 2012 Sep; 16(4):380-6. PubMed ID: 21945189 [TBL] [Abstract][Full Text] [Related]
17. Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia. Freyer G; Kalinka-Warzocha E; Syrigos K; Marinca M; Tonini G; Ng SL; Wong ZW; Salar A; Steger G; Abdelsalam M; DeCosta L; Szabo Z Med Oncol; 2015 Oct; 32(10):236. PubMed ID: 26315712 [TBL] [Abstract][Full Text] [Related]
18. Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study. Rapoport BL; Aapro M; Paesmans M; van Eeden R; Smit T; Krendyukov A; Klastersky J BMC Cancer; 2018 Sep; 18(1):917. PubMed ID: 30249215 [TBL] [Abstract][Full Text] [Related]
19. Unlocking the clinical mysteries of supportive care: a focus on chemotherapy-induced neutropenia, anemia, and mucositis. ONS News; 2004; 19(9 Suppl):27-8. PubMed ID: 15478574 [TBL] [Abstract][Full Text] [Related]
20. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Choi CW; Sung HJ; Park KH; Yoon SY; Kim SJ; Oh SC; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS Am J Hematol; 2003 Aug; 73(4):263-6. PubMed ID: 12879430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]